Blood culture tests market size is projected to expand at 7.9% CAGR from 2024 to 2032. The increasing incidences of bloodstream infections and sepsis across the globe is emphasizing the critical need for accurate and rapid diagnostic tools. The rising technological advancements in blood culture systems for promoting quicker detection and identification of pathogens is contributing to the higher demand for such tests. For instance, in June 2023, Mylab Discovery Solutions, an Indian diagnostic company, introduced PathoCatch Sickle Cell Rapid Test, a strip-based point-of-care test for Sickle Cell Anemia to revolutionize SCA diagnosis and management by providing fast and accurate results directly at the patient’s location.

The growing adoption of automated systems is driving continuous efforts to enhance the sensitivity and specificity of blood culture tests. The growing emphasis on patient safety is increasing the awareness among healthcare professionals about the importance of early and precise diagnosis of bloodstream infections. The integration of molecular diagnostics into blood culture testing methodologies will also complement the industry growth.

The blood culture tests market is categorized into product, method, technology, application, end-use, and region.

Based on product type, the industry value from the instruments segment is projected to rise at 8.1% CAGR from 2024 to 2032, owing to the increasing demand for advanced blood culture systems. The ongoing technological advancements, such as automation and integration of molecular diagnostics, will also contribute to the efficacy of these instruments, driving the product adoption.

Blood culture tests market share from the automated method segment is estimated to witness 8% CAGR through 2032, due to the growing preference for efficient and high-throughput diagnostic solutions. Automated blood culture systems offer rapid and precise pathogen detection in reducing turnaround times. The automation method also enhances the overall efficiency of blood culture testing, pushing the segment growth ahead.

Regionally, the Asia Pacific blood culture tests market is projected to expand at 8.5% CAGR between 2024 and 2032. The growth can be attributed to the rising incidence of infectious diseases, increased awareness about the importance of early and accurate diagnostics, and the higher healthcare infrastructure improvements. The growing emphasis on effective infection control measures and continuous technological advancements in diagnostic procedures will also fuel the regional market expansion.